Why are Incyte shares trading lower today?

Incyte Corporation INCY Fourth-quarter adjusted EPS reached $0.10, compared to $0.93 posted a year ago. Analysts had estimated $0.86.

  • Sales rose 9.3% year-on-year to $862.85 million, ahead of consensus of $813.40 million.
  • The company’s operating expenses increased 20.3% to $752.12 million, with cost of sales up 21%, R&D costs up 16% and general and administrative expenses up 35%.
  • The company reported operating profit of $166.01 million, up from $218.47 million a year ago.
  • Product and royalty revenue increased 20% year-on-year to $812.85 million, driven by net product revenue from Jakafi and Pemazyre and higher product royalty revenue from Olumiant and Tabrecta .
  • The 113% growth in Olumiant’s royalty revenue reflects an increase in net product sales due to the use of Olumiant for COVID-19.
  • In October, Incyte launched its first dermatology product with FDA approval of Opzelura for atopic dermatitis. Nearly 19,000 new patients started Opzelura in the fourth quarter.
  • Cash, cash equivalents and marketable securities totaled $2.3 billion.
  • Advice: Incyte expects FY22 net revenue from Jakafi products to be $2.3 billion – $2.4 billion and net revenue from other hematology/oncology products to $210 million dollars – 240 million dollars.
  • Price Action: INCY shares traded down 4.46% to $70.08 when last checked on Tuesday.

If you don’t use this trading strategy, you are leaving money on the table…

If you look blindly and trade stocks like 99% of traders do, you are missing out on HUGE potential returns. Even new traders who started following this options trading strategy immediately started seeing returns that they wouldn’t have otherwise. With even two trades per month with this strategy, you will start to see the difference in your trading account. Stop wasting time “guessing” and “getting lucky”. Click here to see if you qualify for Benzinga options!


For today only, we’re offering our Benzinga Options Starter newsletter for just $7. This includes two highly sought-after trades per month by lead trader, Nic Chahine. For the same cost of a cup of coffee, less than the cost of a Netflix subscription, and less than the average order at McDonalds, you’ll receive top-tier education and winning business alerts to maximize your portfolio returns. This also includes a 14 day full money back guarantee if you cancel. There is absolutely no risk! Click here now to get started!


Comments are closed.